Company Overview
About FogPharma
FogPharma is a clinical-stage biopharmaceutical company founded in 2015 by Gregory Verdine and headquartered in Cambridge, Massachusetts, developing a novel class of cancer therapeutics based on cell-penetrating mini-proteins (CPMPs). Traditional cancer drugs fall into two broad categories: small molecules that can penetrate cells but struggle to bind complex protein surfaces, and antibodies that bind complex surfaces with high specificity but cannot enter cells. FogPharma's CPMPs are designed to do both — penetrate cell membranes and engage large, complex intracellular protein targets that cause cancer but have historically been considered undruggable.
Business Model & Competitive Advantage
FogPharma has raised $174 million in total funding, including a $100 million Series C in 2023 led by OrbiMed Advisors, with participation from existing investors including Third Rock Ventures, AbbVie Ventures, and GV (formerly Google Ventures). The company's lead program, FOG-001, targets the Wnt/beta-catenin signaling pathway — a driver of cancer proliferation in colorectal, liver, endometrial, and other cancers. Beta-catenin is one of the most frequently mutated oncoproteins in cancer but has not been successfully targeted by approved therapies due to the intracellular location and large surface area of its critical protein interactions.
Competitive Landscape 2025–2026
FogPharma is also pursuing programs targeting FOXM1, a transcription factor implicated in cancer cell survival and drug resistance. The company's scientific co-founder, Gregory Verdine, pioneered the hydrocarbon stapling technology that enables CPMPs to maintain their helical structure and cell-penetrating properties. FogPharma's approach represents a potential new therapeutic modality for cancer types that lack effective targeted therapies, particularly those driven by transcription factors and other historically intractable intracellular targets.
Key Differentiators
Emerging Innovator
FogPharma is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare FogPharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from FogPharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim FogPharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention FogPharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →